ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2024
Operating margin
-38.6%+12418.6 pts over 5 years
Net margin
-39.8%+12185.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +195.3% | +207.1% | +175.5% | +71.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | -2893.0% | -74.0% | -275.7% | |
| Return on assets | – | -59.9% | -26.8% | |
| Current ratio | – | 3.51 | 2.92 | |
| Capex to revenue | 165.6% | 141.9% | 0.5% | |
| Diluted shares | 148M | 630M | 1.51B |
Where the cash went
Fiscal 2020 to 2024, five years combined
Adaptimmune Therapeutics generated $420.18M from operations and spent $45.98M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$420.18M
Used
$45.98M
Capital expenditure$45.98M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-39.8%
×Asset turnover0.67×
×Equity multiplier10.29×
=Return on equity, FY2024-275.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -39.8% | 0.67× | 10.29× | -275.7% |
| FY2023 | -188.9% | 0.20× | 5.04× | -187.6% |
| FY2022 | -609.5% | 0.07× | 2.77× | -115.0% |
| FY2021 | -2571.0% | 0.01× | 1.68× | -57.8% |
| FY2020 | -3286.8% | 0.01× | 1.36× | -56.0% |
| FY2019 | -12225.0% | 0.00× | 1.24× | -74.0% |
| FY2018 | -160.5% | 0.21× | 1.24× | -42.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
3of 7 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-$70.81M
- Cash generatingOperating cash flow above zero-$73.21M
- Return on assets improvedROA up on the prior year-34.6% → -25.1%
- Earnings backed by cashOperating cash flow above net income-$73.21M vs -$70.81M
- Less leverageLong-term debt to assets fell– → 20.4%
- Better liquidityCurrent ratio rose2.85 → 2.92
- No dilutionShare count did not rise1.21B → 1.51B
- Gross margin improvedGross margin up on the prior year– → 99.96%
- More efficientAsset turnover rose0.18 → 0.63